β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged to be one of the most important pathogens both in health care and in community-onset infections. Daptomycin (DAP) is a cyclic anionic lipopeptide recommended for treatment of skin infections, bacteremia, and right-sided endocarditis caused by MRSA. Resistance to DAP (DAP r ) has been reported in MRSA and is mostly accompanied by a parallel decrease in oxacillin resistance, a process known as the “seesaw effect.” Our study provides evidence that the seesaw effect applies to other β-lactams and carbapenems of clinical use, including nafcillin (NAF), cefotaxime (CTX), amoxicillin-clavulanic (AMC), and imipenem (IMP), in heterogeneous DAP r MRSA strains but not in MRSA strains expressing homogeneous β-lactam resistance. The antibacterial efficacy of DAP in combination with β-lactams was evaluated in isogenic DAP-susceptible (DAP s )/Dap r MRSA strains originally obtained from patients that failed DAP monotherapy. Both in vitro (MIC, synergy-kill curve) and in vivo (wax worm model) approaches were used. In these models, DAP and a β-lactam proved to be highly synergistic against both heterogeneous and homogeneous clinical DAP r MRSA strains. Mechanistically, β-lactams induced a reduction in the cell net positive surface charge, reverting the increased repulsion provoked by DAP alone, an effect that may favor the binding of DAP to the cell surface. The ease of in vitro mutant selection was observed when DAP s MRSA strains were exposed to DAP. Importantly, the combination of DAP and a β-lactam prevented the selection of DAP r variants. In summary, our data show that the DAP–β-lactam combination may significantly enhance both the in vitro and in vivo efficacy of anti-MRSA therapeutic options against DAP r MRSA infections and represent an option in preventing DAP r selection in persistent or refractory MRSA infections.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H., & Swaminathan, B. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.9.2233-2239.1995 · Cited by 8,204
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Peschel, A., Otto, M., Jack, R. W., Kalbacher, H., Jung, G., & Götz, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8405 · Cited by 994
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus
Bannerman, T. L., Hancock, G. A., Tenover, F. C., & Miller, J. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.3.551-555.1995 · Cited by 550
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454
Natural products to drugs: daptomycin and related lipopeptide antibiotics
Baltz, R. H., Miao, V., & Wrigley, S. K. (2005) · Natural Product Reports · doi:10.1039/b416648p · Cited by 393
Research works printed but not linked: 1
- NCCLS/CLSI. 2007. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8, 8th ed. NCCLS/CLSI, Wayne, PA.
Cited by
Items 101–146 of 146
Principles of Anti-infective Therapy
Eliopoulos, G. M., & Moellering, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00017-5 · Cited by 10
Cheng, M. P., Lawandi, A., Butler‐Laporte, G., Paquette, K., & Lee, T. C. (2018) · Trials · doi:10.1186/s13063-018-2668-6 · Cited by 9
New advances in management and treatment of cardiac implantable electronic devices infections
Russo, A., Serraino, R., Serapide, F., Trecarichi, E. M., & Torti, C. (2023) · Infection · doi:10.1007/s15010-023-02130-8 · Cited by 9
Lee, J. Y. H., & Howden, B. P. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1041924 · Cited by 9
Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections
Molina, K. C., & Huang, V. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0553-6 · Cited by 9
Daptomycin non-susceptible Staphylococcus aureus at a US medical centre
Velazquez, A., DeRyke, C. A., Goering, R. V., Hoover, V., & Wallace, M. R. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12171 · Cited by 9
Acute Angioedema Triggered by Daptomycin
Gisler, V., Müller, S., Müller, L., Jörg, L., & Sendi, P. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0111-4 · Cited by 9
Hall, A. M., & McTigue, S. M. (2018) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-23.6.490 · Cited by 8
Ledger, E. V. K., & Massey, R. C. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00961-24 · Cited by 8
Investigation of antibacterial and anti-cancer activities of Streptomyces sp SRF1 culture filtrate
Sangdee, K., Buranrat, B., Seephonkai, P., Surapong, N., & Sangdee, A. (2018) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v16i11.21 · Cited by 8
Podoll, J. D., Olson, J., Wang, W., & Wang, X. (2021) · Antibiotics · doi:10.3390/antibiotics10030315 · Cited by 7
Sánchez, E. G., la Torre, L. F., Hernández‐Gómez, A., Alonso‐Castro, Á. J., Serafín‐Higuera, N., Terán‐Rosales, F., Bologna‐Molina, R. E., & Isiordia‐Espinoza, M. A. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12832 · Cited by 7
Gregori, S. D., SILVESTRI, A. D., Capone, M., Monzillo, V., Giordani, P., Bruno, R., & Seminari, E. M. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241296232 · Cited by 6
Adjunctive β-lactams for Staphylococcus aureus bacteremia: a narrative review
Chastain, D. B., White, B. P., Henao‐Martínez, A. F., Tu, P. J., Bland, C. M., Foster, R. A., & Cluck, D. B. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361251343969 · Cited by 6
Management of Periprosthetic Joint Infection
Lora-Tamayo, J., & Murillo, Ó. (2017) · Springer eBooks · doi:10.1007/978-3-319-65250-4_4 · Cited by 6
Sulaiman, J. E., Long, L., Qian, P., & Lam, H. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.970146 · Cited by 6
Zazharskyi, V. V., Zaslavskyi, O., Sosnitskyi, O. I., Тішкіна, Н. М., Zazharska, N. M., Biben, І. A., Sosnitska, A. O., & Brygadyrenko, V. V. (2024) · Regulatory Mechanisms in Biosystems · doi:10.15421/022454 · Cited by 6
Şanal, L., Yılmaz, N., Uludağ, H. A., rk, R. O. Z. U., Sen, S., & Cesur, S. (2018) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.66445 · Cited by 6
Davis, K. P., McDermott, L. A., Snydman, D. R., & Aldridge, B. B. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00976-24 · Cited by 6
Updates on Combination Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia
Blackman, A. L., Rubin, E. C., Broadbent, E. K., & Brade, K. D. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00737-8 · Cited by 5
Lipopolysaccharide-targeting treatments for multidrug-resistant Pseudomonas aeruginosa
Wang, M. C., & Kirienko, N. V. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639679 · Cited by 5
Chen, M., Jiang, S., Sun, L., Wang, H., Di, L., Liu, Y., Zhang, Y., Zhuang, H., Hong, Y., Wang, Z., et al. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107469 · Cited by 5
Morales‐Cartagena, A. (2015) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v5.i2.14 · Cited by 4
Umemura, T., Kato, H., Asai, N., Hagihara, M., Hirai, J., Yamagishi, Y., & Mikamo, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29811 · Cited by 4
Colston, J., Scarborough, M., Collier, J. D., & Bowler, I. C. J. W. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-009529 · Cited by 4
Antibiotic and Antifungal Therapy in the ICU
Daley, M. J., Hodge, E. K., & Rose, D. T. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-71712-8_36 · Cited by 3
Tamas, V., Ulloa, E. R., Kumaraswamy, M., Dahesh, S., Zurich, R. H., Nizet, V., & Coady, A. M. (2025) · Antibiotics · doi:10.3390/antibiotics14121284 · Cited by 3
Cave, K., & Gould, I. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00138-9 · Cited by 2
Cañas, M.-A., García‐González, J., Paz, D. L., Cuervo, G., Krivak, F., Nin-Blanch, J., Meneses, M. H., Falces, C., Maristany, M., Perissinotti, A., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag136 · Cited by 2
Dabul, A. N. G. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2014.tde-13032014-085110 · Cited by 2
Scaffidi, S. J., Zhang, R., Jia, Y., & Yu, W. (2026) · Journal of Bacteriology · doi:10.1128/jb.00523-25 · Cited by 2
Expression of mecA increases daptomycin tolerance in Staphylococcus aureus
Ledger, E. V. K., Recker, M., & Massey, R. C. (2025) · mBio · doi:10.1128/mbio.02250-25 · Cited by 2
The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance
Caroleo, M. C., Pisano, M., Cione, E., Scumaci, D., Cai, T., Gallelli, L., & Leo, A. (2026) · Antibiotics · doi:10.3390/antibiotics15070691 · Cited by 1
Strategies for Circumventing Bacterial Resistance Mechanisms
Fisher, J. F., Johnson, J. W., & Mobashery, S. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_12 · Cited by 1
Microbiological Background: Biofilm, Culturing, and Antibiotics
Bartoletti, M., & Viale, P. (2020) · Springer eBooks · doi:10.1007/978-3-030-46255-0_2 · Cited by 1
Shah, S., Clarke, L. G., & Padival, S. (2024) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2024-004334
Combined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Staphylococcus aureus Regulatory RNAs Driving Fitness upon Antibiotic Exposure
Liu, W. (2018) · theses.fr (ABES) · doi:10.70675/1ab43e4bz428bz410ez90c9z8b5f463c1e38
Woischnig, A.-K., Küehl, R., Cornillet, D., Iizuka, A., Schumacher, M., Lang, C., Egli, A., Keller, P. M., Giulieri, S. G., Morgenstern, M., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00876-26
Strategies for Circumventing Bacterial Resistance Mechanisms
Fisher, J. F., Johnson, J. W., & Mobashery, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_12-1
Proteasome Inhibitors with a Focus on Bortezomib
Barley, K. M., & Parekh, S. S. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-75184-9_3
Harnessing Interspecies Antagonism to Enhance Antibiotic Efficacy
Radlinski, L. C. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/efft-zk73
Sulaiman, J. E., Long, L., Qian, P.-Y., & Lam, H. (2022) · doi:10.3389/fmicb.2022.970146.s002
Lobello, R. (2017) · Electronic Theses and Dissertations Repository (University of Pisa)
Davis, K. P., Poonawala, H., Murphy, C., Thorpe, C. M., Rosato, A. E., & Aldridge, B. B. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-25
Self-citationNgoje, P. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
Metadata
- Authors
- Mehta, S., Singh, C., Plata, K. B., Chanda, P. K., Paul, A., Riosa, S., Rosato, R. R., & Rosato, A. E.
- Affiliations
- Houston Methodist Research Institute (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-12
- Volume
- 56
- Issue
- 12
- Pages
- 6192-6200
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3497165
- OpenAlex
- W2146598854
- Cited by
- 142
- References
- 49
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 14 · 2017: 11 · 2016: 13 · 2015: 20 · 2014: 12 · 2013: 15 · 2012: 2
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI080688)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- daptomycin, methicillin-resistant Staphylococcus aureus, beta-lactam antibiotics, carbapenems, combination therapy, drug synergy, daptomycin resistance, seesaw effect, oxacillin resistance, nafcillin, cefotaxime, imipenem, mutant selection, cell surface charge, MRSA skin infection
- MeSH terms
- Animals, Anti-Bacterial Agents, Cefotaxime, DNA, Drug Synergism, Insecta, Larva, Microbial Sensitivity Tests, Mutation, Nafcillin, Oxacillin, Staphylococcal Infections, Imipenem, Daptomycin, Amoxicillin-Potassium Clavulanate Combination, Drug Resistance, Bacterial, beta-Lactams, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.